Barclays
RXRX icon

Barclays’s Recursion Pharmaceuticals RXRX Stock Holding History

Barclays’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$951K Buy
230,273
+112,213
+95% +$380K ﹤0.01% 3088
2026
Q2 		$433K Sell
118,060
-35,211
-23% -$117K ﹤0.01% 3310
2026
Q1 		$471K Sell
153,271
-1,315,991
-90% -$5.09M ﹤0.01% 3222
2025
Q4 		$6.01M Sell
1,469,262
-80,964
-5% -$401K ﹤0.01% 2068
2025
Q3 		$7.57M Buy
1,550,226
+385,537
+33% +$2.02M ﹤0.01% 1883
2025
Q2 		$5.89M Buy
1,164,689
+573,683
+97% +$2.82M ﹤0.01% 1981
2025
Q1 		$3.13M Sell
591,006
-42,119
-7% -$307K ﹤0.01% 2287
2024
Q4 		$4.28M Sell
633,125
-64,307
-9% -$432K ﹤0.01% 2296
2024
Q3 		$4.6M Buy
697,432
+304,278
+77% +$2.18M ﹤0.01% 2164
2024
Q2 		$2.95M Buy
393,154
+78,853
+25% +$688K ﹤0.01% 1866
2024
Q1 		$3.13M Sell
314,301
-282,257
-47% -$3.14M ﹤0.01% 2189
2023
Q4 		$5.88M Buy
596,558
+38,787
+7% +$277K ﹤0.01% 1953
2023
Q3 		$4.27M Buy
557,771
+369,103
+196% +$3.68M ﹤0.01% 1412
2023
Q2 		$1.41M Buy
188,668
+446
+0.2% +$3.12K ﹤0.01% 2099
2023
Q1 		$1.26M Sell
188,222
-108,378
-37% -$860K ﹤0.01% 2561
2022
Q4 		$2.29M Buy
296,600
+184,366
+164% +$1.81M ﹤0.01% 2180
2022
Q3 		$1.2M Buy
112,234
+91,762
+448% +$929K ﹤0.01% 2103
2022
Q2 		$166K Sell
20,472
-2,556
-11% -$17.1K ﹤0.01% 3540
2022
Q1 		$165K Buy
+23,028
New +$245K ﹤0.01% 3538

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays's RXRX Position: Q3 2026 in Review

Barclays increased its Recursion Pharmaceuticals (RXRX) stake by 95% in Q3 2026, buying an estimated $380K and bringing the position to 230,273 shares worth $951K. The position accounts for ﹤0.01% of the portfolio, ranked #3088.

Barclays first reported a position in RXRX in Q1 2022 and has held it in 19 quarters since. The position peaked at $7.57M in Q3 2025. 178 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Barclays held 230,273 shares of Recursion Pharmaceuticals worth $951K as of Q3 2026.
  • Barclays bought 112,213 Recursion Pharmaceuticals shares in Q3 2026, an estimated $380K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3088 holding.
  • Barclays first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Recursion Pharmaceuticals position peaked at $7.57M in Q3 2025.
  • 178 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.